Actuate Therapeutics, Inc. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Actuate Therapeutics, Inc. (ACTU) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $10.13 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- Actuate Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $5.06K, a 0.02% increase year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $5.06K, a 0.02% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $5.06K, a 0.28% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $5.06K.
- Actuate Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $20.25K, a 8.63% increase from fiscal 2024.
- Actuate Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $18.64K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $10.13K 10-Q · filed 2026-08-14 | $15.19K derived: sum of 3 quarters · filed 2026-08-14 | $20.25K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.06K 10-Q · filed 2026-05-14 | $10.12K derived: sum of 2 quarters · filed 2026-05-14 | $15.19K derived: sum of 3 quarters · filed 2026-05-14 | $20.25K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $5.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $10.13K derived: sum of 2 quarters · filed 2026-03-26 | $15.19K derived: sum of 3 quarters · filed 2026-08-14 | $20.25K 10-K · filed 2026-03-26 |
| 2025-09-30 | $5.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $10.13K derived: sum of 2 quarters · filed 2026-08-14 | $15.19K 10-Q · filed 2025-11-13 | $20.26K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $5.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $10.13K 10-Q · filed 2026-08-14 | $15.20K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-03-31 | $5.06K 10-Q · filed 2026-05-14 | $10.14K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $5.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $18.64K 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $13.56K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |